From the 1940s-1990s, chloroquine was the mainstay of malaria therapy worldwide. Selection of P.falciparum-resistant isolates was first reported in Southeast Asia (Thai-Cambodian border) and South America (Colombia) in the 1950s. Since then chloroquine resistance has spread far beyond the first focus and is now found in all parts of the world where malaria is endemic. Chloroquine resistance has emerged independently less than ten times in the past 50 years. Can chloroquine be used in antimalarial treatment at present status both in children and adult populations?